CERTHealthcare · Health Information ServicesThe 12 Wall Street analysts covering Certara, Inc. hold a median 12-month price target of $8.2 — -2.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Certara, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (90): The share count has been shrinking and the company is not leaning on new borrowing.
Revisions (33): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CERT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −2.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | $6.50 → $7.50 |
| 12 May 2026 | Baird | Maintains | Neutral | — |
| 12 May 2026 | Baird | Maintains | Neutral | $7.00 → $6.00 |
| 12 May 2026 | Barclays | Maintains | Equal-Weight | $8.00 → $6.50 |
| 12 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 May 2026 | BMO Capital | Maintains | Market Perform | — |
| 12 May 2026 | BMO Capital | Maintains | Market Perform | $7.00 → $6.00 |
| 12 May 2026 | Craig-Hallum | Maintains | Hold | — |
| 12 May 2026 | Craig-Hallum | Maintains | Hold | $10 → $8.00 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $11 → $10 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2026 | Stephens & Co. | Maintains | Overweight | — |
| 12 May 2026 | Stephens & Co. | Maintains | Overweight | $10 → $9.00 |
| 13 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 6 Mar 2026 | Barclays | Downgrade | Equal-Weight | — |
| 27 Feb 2026 | Barclays | Maintains | Overweight | — |
| 8 Jan 2026 | Keybanc | Maintains | Overweight | — |
| 6 Jan 2026 | Leerink Partners | Upgrade | Outperform | — |
| 18 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Dec 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CERT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 41% of US stocks
Cheaper than 63% of US stocks
Cheaper than 24% of US stocks
Higher than 29% of US stocks
Higher than 25% of US stocks
Higher than 76% of US stocks
Higher than 32% of US stocks
Higher than 17% of US stocks
Higher than 42% of US stocks
Higher than 48% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Certara, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cerrado Gold Inc. (CERT:CA) held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha.
Why it matters — The transcript provides CERT watchers with the company's full Q2 2026 commentary and management discussion.
Seeking Alpha published the transcript of Certara, Inc.'s (CERT) Q2 2026 earnings call. The transcript contains the company's presentation and discussion from its second-quarter earnings call.
Why it matters — The transcript gives CERT watchers access to management's full commentary on the quarter, beyond the headline earnings figures.
Certara reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure, and artificial intelligence strategy.
Why it matters — A CERT watcher would care because the company reaffirmed its full-year revenue outlook while signaling continued restructuring of its commercial organization, cost structure, and AI strategy.
Certara reported Q2 earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.10 per share, though above the $0.07 per share earned a year ago. Revenues also lagged estimates in the quarter.
Why it matters — A CERT watcher would note that the quarter fell short of Wall Street's earnings and revenue expectations despite showing year-over-year earnings growth.
Certara reported its second quarter 2026 financial results, appointed Julien Perrier as Chief Commercial Officer, completed a previously authorized $100 million share repurchase program, and had its board authorize an additional $50 million under the repurchase program. The company reaffirmed its 2026 revenue guidance.
Why it matters — A CERT watcher would care because the company expanded its buyback program and reaffirmed guidance, which may signal management's confidence in the business outlook.
The 12 Wall Street analysts covering Certara, Inc. have a median 12-month price target of $8.2, with estimates ranging from $7 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Certara, Inc., 4 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Certara, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Certara, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (90 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies -2.7% from the last close, and Ticker Nerd's factor model ranks Certara, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Certara, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CERT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $9 over the next 12 months.
Certara, Inc. returned -21.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Certara, Inc. is a global leader in biosimulation science, technology, and consulting services that transform drug development through model-informed drug development (MIDD).
The most recent item we track (Seeking Alpha, 19 Aug 2026): "Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript". Cerrado Gold Inc. (CERT:CA) held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha.
Certara, Inc. is a global leader in biosimulation science, technology, and consulting services that transform drug development through model-informed drug development (MIDD). The company provides proprietary biosimulation platforms, software products, and expert consulting services designed to help biopharmaceutical and biotech organizations design better clinical trials, optimize drug development decisions, and accelerate regulatory approval processes. Certara's software solutions include mechanistic and empirical biosimulation models, pharmacometric analysis tools, and the Pinnacle 21 family of clinical data management products. The company also offers specialized services spanning drug development strategy, clinical pharmacology, regulatory science, and submission management across major health agencies including the FDA, EMA, and China's NMPA. In 2024, Certara acquired Chemaxon to strengthen its drug discovery capabilities through chemical property prediction and in-silico development tools. The platform integrates artificial intelligence capabilities within validated scientific frameworks to enhance modeling productivity and data connectivity. Certara's solutions serve more than 2,600 life sciences organizations globally, including 38 of the top 40 biopharmaceutical companies by R&D spend, with customers receiving the majority of novel drug approvals from the FDA. Founded in 2008 and headquartered in Radnor, Pennsylvania, Certara operates across the Americas, Europe, Middle East, Africa, and Asia Pacific.
CEO Mr. Jon Resnick · 1,515 employees · United States · https://www.certara.com